La vendita allo scoperto per NeuroOne Medical Tech dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di NeuroOne Medical Tech. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

NeuroOne Medical Tech (NASDAQ:NMTC) Azioni, Report sulle vendite allo scoperto

NeuroOne Medical Tech

NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.

NeuroOne Medical Technologies Corporation - Common Stock

NeuroOne Medical Technologies Corp

Claros Mortgage Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMTG#NYSE">CMTG</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.10 by 120 percent. The company reported quarterly sales of $64.877 million which beat the analyst consensus estimate of $57.180 million by 13.46 percent. This is a 19.46 percent decrease over sales of $80.553 million the same period last year.

Earnings

Earnings Beats

News

CMTG

Claros Mortgage Trust Q3 2024 Adj. EPS $0.22 Beats $0.10 Estimate, Sales $64.877M Beat $57.180M Estimate

Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.90) by 106.67 percent. The company reported quarterly sales of $1.667 million which beat the analyst consensus estimate of $611.000 thousand by 172.83 percent. This is a 250.95 percent increase over sales of $475.000 thousand the same period last year.

CBUS

Cibus Q3 2024 Adj. EPS $0.06 , Sales $1.667M Beat $611.000K Estimate

President-elect Donald Trump has appointed his campaign leader, Susie Wiles, as his chief of staff. This marks the first time in US history that a woman has been appointed to this influential position.
What Happened: Wiles, a seasoned GOP operative from Florida, will assume her new role when Trump takes office in January. Trump lauded Wiles for her pivotal role in his successful 2016 and 2020 campaigns, <a href="https://thehill.com/homenews/4979786-susie-wiles-chief-of-staff/">reported</a> The Hill.
&#8220;Susie is tough, smart, innovative, and is universally admired and respected. Susie will continue to work tirelessly to Make America Great Again,&#8221; said Trump, reported The Hill.
He said, &#8220;It is a well deserved honor to have Susie as the first-ever female Chief of Staff in United States history. I have no doubt that she will make our country proud.&#8221;
Wiles, known for her low-profile approach, spearheaded Trump&#8217;s Florida operations during the 2016 campaign and later collaborated with Ron DeSantis (R) on his gubernatorial campaign. However, she left DeSantis&#8217;s team due to escalating tensions.
The chief of staff role, second only to the president in terms of influence, will see Wiles managing Trump and his team, a task that proved challenging during his first term. Trump&#8217;s initial choice for the role, Reince Priebus, was replaced after six months by John Kelly, who later became a vocal critic of Trump.
See Also: <a href="https://www.benzinga.com/news/24/11/41710411/market-analyst-who-predicted-trumps-2016-win-and-bidens-2020-victory-now-sees-former-president-retak?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Market Analyst Who Predicted Trump&#8217;s 2016 Win And Biden&#8217;s 2020 Victory, Now Sees Former President Retaking The White House With &#8216;Large Majority Of Swing States&#8217;</a>
Why It Matters: Wiles&#8217; appointment comes on the <a href="https://www.benzinga.com/news/24/11/41766547/trump-gives-victory-speech-in-florida-as-winning-pennsylvania-puts-him-at-brink-of-victory-vows-to-f">heels of Trump&#8217;s victory</a> in the 2024 presidential election. Trump&#8217;s win, which he described as &#8220;the greatest political movement of all time,&#8221; was followed by a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41807254/trump-election-raises-odds-of-roaring-2020s-scenario-veteran-wall-street-investor-s">surge in the U.S. stock market</a>, with analysts predicting a new &#8220;Roaring 2020s&#8221; scenario.
On Wednesday, after Trump won the election, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) shot up 2.5% to establish new record highs. The small-caps fund iShares Russell 2000 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) spiked 5.8%.
However, Trump also hinted at a <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">potential senior role</a> for Robert Kennedy Jr. to advance his &#8220;Make America Healthy Again&#8221; agenda, causing uncertainty in pharmaceutical stocks.
With Wiles at the helm as chief of staff, it remains to be seen how these developments will unfold and shape the course of Trump&#8217;s second term in office.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Politics

General

Trump Appoints Susie Wiles As First Woman Chief Of Staff In US History, Calls Her Tough, Smart And Innovative

Galiano Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GAU#AMEX">GAU</a>) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.04 by 75 percent. This is a 40 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $71.130 million which missed the analyst consensus estimate of $78.000 million by 8.81 percent. This is a 5.22 percent increase over sales of $67.600 million the same period last year.

Earnings Misses

Galiano Gold Q3 2024 Adj. EPS $0.07 Beats $0.04 Estimate, Sales $71.130M Miss $78.000M Estimate

HireQuest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQI#NASDAQ">HQI</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.16 by 25 percent. The company reported quarterly sales of $9.416 million which beat the analyst consensus estimate of $8.950 million by 5.21 percent. This is a 1.56 percent increase over sales of $9.271 million the same period last year.

HireQuest Q3 2024 Adj. EPS $0.20 Beats $0.16 Estimate, Sales $9.416M Beat $8.950M Estimate

Donald Trump will return to the White House and will bring major changes to the country's tax, AI and energy policies. RBC Capital Markets analyst Deane Dray highlighted some of the companies that may benefit <a href="https://www.benzinga.com/government/24/11/41828468/trump-says-hed-replace-income-taxes-with-tariffs-the-potential-economic-fallout">from Trump's policies. </a>
Fossil Fuel/ Energy Independence: Trump's plans for energy independence would reverse many of the Biden administration's policies in order to reinvigorate the fossil fuel industry. He aims to expand the construction of pipelines, grids, ports and refineries and emphasizes utilizing domestic oil, gas and coal resources. Dray pointed to Flowserve Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLS#NYSE">FLS</a>) and Emerson Electric Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) as potential beneficiaries of Trump's energy policies. 
Read Next: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
Rollback of IRA/ Reduced Clean Energy Investments: Trump has said he plans<a href="https://www.benzinga.com/news/24/07/39854007/trump-says-he-will-end-the-electric-vehicle-mandate-on-day-one-days-after-tesla-ceo-elon-musks-endor"> to eliminate</a> many vehicle emissions standards under the Environmental Protection Agency as well as many EV incentives included in the Biden administration&#8217;s Inflation Reduction Act (IRA). 
The RBC analyst again pointed to oil and gas companies as the key companies that could benefit from these potential policy adjustments, but cautioned it is too early to tell what the impacts might be for nuclear power companies. 
More Flexible/Reduced AI Regulation: RBC expects a Trump administration to be in favor of Big Tech and AI developers as he has called for a review of "unnecessary and burdensome regulations" on AI. The firm also pointed out that multi-industry data center-exposed stocks outperformed the sector by 500 basis points the day after Trump won the election. 
Dray said multi-industry companies involved in data centers that could benefit from Trump's less restrictive AI policies include nVent Electric Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVT#NYSE">NVT</a>) and Eaton Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>). 
Lower Corporate Tax Rate: Trump <a href="https://www.benzinga.com/government/24/10/41623850/trump-vs-harris-how-the-candidates-corporate-tax-proposals-stack-up">shared his plans</a> to lower the corporate tax rate to 15% for companies that make their products in the U.S. The RBC analyst sees lower corporate tax rates could lead to more reshoring from semiconductor and pharmaceutical companies and potentially more investment in the US. 
Dray pointed to Roper Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) specifically, but most publicly traded companies could benefit from lower tax rates. 
The Takeaway: "The bottom line is that early stock moves are playing out according to script, with the early stock outperformers being the electricals and oil and gas exposed names," Dray wrote. 
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41774549/trumps-big-tech-policies-what-gop-victory-means-for-apple-google-microsoft">Trump&#8217;s Big Tech Policies: What GOP Victory Means For Apple, Google, Microsoft</a></li>
</ul>
Photo: Shutterstock

Government

Movers

How To Play The 'Trump Trade' For AI, Energy, Taxes: Analyst Says 5 Stocks Could Shine

Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) reported quarterly losses of $(1.82) per share which beat the analyst consensus estimate of $(2.03) by 10.34 percent. The company reported quarterly sales of $1.650 million which beat the analyst consensus estimate of $1.635 million by 0.92 percent. This is a 9.19 percent decrease over sales of $1.817 million the same period last year.

AVGR

Avinger Q3 2024 GAAP EPS $(1.82) Beats $(2.03) Estimate, Sales $1.650M Beat $1.635M Estimate

Globalstar (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#AMEX">GSAT</a>) raises FY2024 sales outlook from $235.00 million-$250.00 million to $245.00 million-$250.00 million.

Guidance

GSAT

Globalstar Raises FY2024 Sales Guidance from $235.00M-$250.00M to $245.00M-$250.00M

VistaGen Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTGN#NASDAQ">VTGN</a>) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.39) by 7.69 percent. This is a 36.36 percent increase over losses of $(0.66) per share from the same period last year. The company reported quarterly sales of $183.000 thousand which missed the analyst consensus estimate of $223.333 thousand by 18.06 percent. This is a 34.10 percent decrease over sales of $277.700 thousand the same period last year.

VTGN

VistaGen Therapeutics Q2 2025 GAAP EPS $(0.42) Misses $(0.39) Estimate, Sales $183.000K Miss $223.333K Estimate

Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) reported quarterly losses of $(1.72) per share. This is a 37.6 percent decrease over losses of $(1.25) per share from the same period last year. The company reported quarterly sales of $78.795 million which beat the analyst consensus estimate of $73.225 million by 7.61 percent. This is a 25.62 percent increase over sales of $62.723 million the same period last year.

NUTX

Nutex Health Q3 2024 GAAP EPS $(1.72) Down From $(1.25) YoY, Sales $78.795M Beat $73.225M Estimate

Petroleo Brasileiro S.A.- Petrobras American Depositary Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBR#NYSE">PBR</a>) reported quarterly earnings of $0.92 per share which beat the analyst consensus estimate of $0.78 by 17.95 percent. The company reported quarterly sales of $23.366 billion which beat the analyst consensus estimate of $22.574 billion by 3.51 percent. This is a 8.56 percent decrease over sales of $25.552 billion the same period last year.

PBR/A

Petroleo Brasileiro S.A.- Petrobras American Depositary Shares Q3 2024 GAAP EPS $0.92 Beats $0.78 Estimate, Sales $23.366B Beat $22.574B Estimate

MannKind (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNKD#NASDAQ">MNKD</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.03 by 100 percent. This is a 200 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $70.079 million which missed the analyst consensus estimate of $74.500 million by 5.93 percent. This is a 36.73 percent increase over sales of $51.253 million the same period last year.

MNKD

MannKind Q3 2024 Adj. EPS $0.06 Beats $0.03 Estimate, Sales $70.079M Miss $74.500M Estimate

Goldman Sachs BDC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSBD#NYSE">GSBD</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.55 by 3.64 percent. The company reported quarterly sales of $110.413 million which missed the analyst consensus estimate of $115.264 million by 4.21 percent. This is a 8.03 percent decrease over sales of $120.056 million the same period last year.

GSBD

Goldman Sachs BDC Q3 2024 Adj. EPS $0.57 Beats $0.55 Estimate, Sales $110.413M Miss $115.264M Estimate

BanColombia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIB#NYSE">CIB</a>) reported quarterly earnings of $1.49 per share which beat the analyst consensus estimate of $1.43 by 4.2 percent. The company reported quarterly sales of $1.257 billion which missed the analyst consensus estimate of $1.573 billion by 20.10 percent. This is a 4.92 percent increase over sales of $1.198 billion the same period last year.

BanColombia Q3 2024 GAAP EPS $1.49 Beats $1.43 Estimate, Sales $1.257B Miss $1.573B Estimate

The 2028 presidential election will be held on Nov. 7, 2028, and is over 1,400 days away but that hasn't stopped sportsbooks and prediction markets from forecasting who will win the next election after Donald Trump claimed victory in the<a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election"> 2024 presidential election.</a>
2028 Election Betting Odds: While betting on U.S. elections is illegal for American sportsbooks, there are betting odds at sportsbooks around the world. Prediction markets and online stock brokerages have also<a href="https://www.benzinga.com/fintech/24/11/41783293/robinhood-reports-record-overnight-trading-volume-400-million-2024-election-contracts-traded"> launched regulated election contract options</a> in recent months.
Here is an early look at the 2028 election betting odds.
From Bookies.com, here are the current betting <a href="https://bookies.com/news/2028-us-presidential-election-odds-who-will-succeed-donald-trump">odds</a>:
<ul>
<li>J.D. Vance (Republican): +450</li>
<li>Gavin Newsom (Democrat): +575</li>
<li>Ron DeSantis (Republican): +700</li>
<li>Michelle Obama (Democrat): +950</li>
<li>Josh Shapiro (Democrat): +1,000</li>
<li>Kamala Harris (Democrat): +1,200</li>
<li>Andy Beshear (Democrat): +1,200</li>
<li>Nikki Haley (Republican): +1,200</li>
<li>Vivek Ramaswamy (Republican): +1,300</li>
<li>Wes Moore (Democrat): +1,700</li>
<li>Tom Cotton (Democrat): +1,700</li>
<li>Glenn Youngkin (Republican): +2,500</li>
<li>Aaron Rodgers (Independent): +3,000</li>
<li>Dwayne Johnson (Democrat): +3,500</li>
<li>Mark Cuban (Democrat): +3,500</li>
<li>Field (All others including Gretchen Whitmer, Marco Rubio, Ted Cruz): +2,000</li>
</ul>
Here are the current betting odds from SportsBettingDimes:
<ul>
<li>J.D. Vance (Republican): +300</li>
<li>Michelle Obama (Democrat): +500</li>
<li>Gavin Newsom (Democrat): +550</li>
<li>Ron DeSantis (Republican): +800</li>
<li>Tulsi Gabbard (Republican): +1,000</li>
<li>Hillary Clinton (Democrat): +1,400</li>
<li>Tucker Carlson (Republican): +1,400</li>
<li>Nikki Haley (Republican): +2,500</li>
<li>Oprah Winfrey (Democrat): +2,500</li>
<li>Kamala Harris (Democrat): +2,500</li>
</ul>
Bet365 does not currently list individual betting odds for who will win but has the option to bet on which party will win with Republicans favored at -150 implying a 60% chance of winning with Democrats the underdog at +120, as reported by <a href="https://www.covers.com/politics/2028-us-election-odds-republican-party-favored-nov-6-2024">Covers</a>.
Prediction market Kalshi, which is legal to U.S. bettors, also has several betting markets open for 2028 including the winning <a href="https://kalshi.com/markets/kxpresparty/party-winning-presidency">party </a>with Republicans at 49% and Democrats at 51%.
Here are the betting <a href="https://kalshi.com/markets/kxpresnomr/republican-primary-winner">odds </a>on Kalshi for the Republican Party nominee for the 2028 election:
<ul>
<li>J.D. Vance: 57%</li>
<li>Donald Trump Jr.: 7%</li>
<li>Ron DeSantis: 6%</li>
<li>Donald Trump: 4%</li>
<li>Glenn Youngkin: 4%</li>
<li>Vivek Ramaswamy: 4%</li>
</ul>
The 22nd Amendment currently would keep Trump from serving more than two terms in the White House, but he's included in Kalshi's odds here.
Here are the betting <a href="https://kalshi.com/markets/kxpresnomd/democratic-primary-winner#kxpresnomd-28">odds </a>on Kalshi for the Democrat Party nominee for the 2028 election:
<ul>
<li>Gavin Newsom: 16%</li>
<li>Josh Shapiro: 16%</li>
<li>Gretchen Whitmer: 14%</li>
<li>Pete Buttigieg: 11%</li>
<li>Wes Moore; 9%</li>
<li>J.B. Pritzker: 9%</li>
<li>Alexandria Ocasio-Cortez: 7%</li>
<li>Michelle Obama: 6%</li>
<li>Kamala Harris: 2%</li>
</ul>
Polymarket, which <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41694948/trump-polymarket-whale-has-30m-bet-on-former-president-winning-2024-election-my-intent-is-">had many prediction markets</a> on the 2024 election does not currently offer 2028 markets. The decentralized platform allows users to deposit funds using USDC (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) via the Polygon (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/matic/usd">MATIC</a>) network or directly from a crypto account with Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>). The platform will be closely watched in the coming months to see who takes the early lead in 2028 election betting.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent110724">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Polymarket saw over $3 billion bet on the 2024 election winner market with various other markets attracting high betting volume.
Kalshi had over $100 million wagered on<a href="https://www.benzinga.com/general/politics/24/11/41701133/more-than-100m-wagered-on-presidential-race-on-kalshi"> the 2024 election outcome.</a>
Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) had over 400 million contracts traded during the 2024 election.
While betting on the outcomes of U.S. elections is not legal at sportsbooks for America, people around the world were placing wagers along with prediction markets and brokerages trading contracts to take advantage of strong user demand.
By the time the 2028 election rolls around there could be even more betting options and election betting<a href="https://www.benzinga.com/general/sports-betting/23/05/32244769/exclusive-draftkings-benefits-from-non-nfl-sports-growth-eyes-horse-racing-and-election-be"> could be legal at sportsbooks. </a>While things could look different in the coming years, the betting odds above will likely look different as candidates decide to run or withdraw their names from consideration.
It's likely not a surprise that Vance is the early betting favorite as the future vice president won the 2024 election ticket with Trump and would be the frontrunner for the Republican Party. The big question is if Harris will run for president again and if not her, who will be the frontrunner for the Democratic Party.
Harris <a href="https://www.benzinga.com/general/sports-betting/24/10/41347270/trump-vs-harris-2024-election-polls-sportsbooks-betting-odds-show-different-winners-for-20">was the favorite </a>at +350 for the 2024 election after Joe Biden won the 2020 election as the current president originally said he would not run a second term. Biden and Trump trailed Harris in January 2021 betting odds to win the 2024 race at +400 and +650, respectively.
With Biden running again, the odds favored Biden, Trump and DeSantis, who ran in the Republican primary, for many months. With Biden dropping out, sportsbooks favored Harris before the odds shifted to Trump in the months leading up to the 2024 election.
While an Independent candidate has never won the election, the listing of Rodgers, who is the quarterback of the NFL's New York Jets, has captured some attention.
"I can't believe we live in a world where my QB has better odds to win the 2028 presidential election than my team does to win the Super Bowl," X user @blakenyjets <a href="https://x.com/blakenyjets/status/1854291783754363114">said</a>.
The New York Jets, who started the season as one of the favorites to win Super Bowl LIX, are currently 3-6 and the odds at DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) of a Super Bowl victory are +2,500 today.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41819799/polymarket-ceo-on-election-night-it-looked-like-a-done-deal-on-platform-but-just-watching-">Polymarket CEO On Election Night: &#8216;It Looked Like A Done Deal&#8217; On Platform, But Just Watching TV &#8216;You Would Think It&#8217;s Neck And Neck&#8217;</a></li>
</ul>
Photo: Meeboonstudio via Shutterstock

Sports Betting

$ETH

$MATIC

$USDC

DKNG

HOOD

USDC

2028 Election Betting Odds: Where Do J.D. Vance, Michelle Obama, Mark Cuban, Ron DeSantis, Kamala Harris Rank?

SANUWAVE Health (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SNWV#OTC">SNWV</a>) reported quarterly losses of $(6.49) per share. This is a 42.31 percent increase over losses of $(11.25) per share from the same period last year. The company reported $9.36 million in sales this quarter. This is a 88.98 percent increase over sales of $4.95 million the same period last year.

SNWV

SANUWAVE Health Q3 EPS $(6.49) Up From $(9.95) YoY, Sales $9.36M Up From $4.95M YoY

Freehold Royalties (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FRHLF#OTC">FRHLF</a>) reported quarterly earnings of $0.12 per share. This is a 42.86 percent decrease over earnings of $0.21 per share from the same period last year. The company reported $54.17 million in sales this quarter. This is a 13.73 percent decrease over sales of $62.79 million the same period last year.

FRHLF

Freehold Royalties Q3 EPS $0.12 Down From $0.21 YoY, Sales $54.17M Down From $62.79M YoY

Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.01 by 300 percent. This is a 180 percent increase over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $30.198 million which beat the analyst consensus estimate of $28.376 million by 6.42 percent. This is a 2.46 percent increase over sales of $29.474 million the same period last year.

JYNT

Joint Q3 2024 Adj. EPS $0.04 Beats $0.01 Estimate, Sales $30.198M Beat $28.376M Estimate

Tucows (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCX#NASDAQ">TCX</a>) reported quarterly losses of $(2.03) per share. This is a 2.87 percent increase over losses of $(2.09) per share from the same period last year. The company reported $92.30 million in sales this quarter. This is a 6.12 percent increase over sales of $86.97 million the same period last year.

Tucows Q3 EPS $(2.03) Up From $(2.09) YoY, Sales $92.30M Up From $86.97M YoY

Iamgold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.10 by 80 percent. This is a 1900 percent increase over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $438.900 million which missed the analyst consensus estimate of $438.910 million by 0 percent. This is a 95.50 percent increase over sales of $224.500 million the same period last year.

Iamgold Q3 2024 Adj. EPS $0.18 Beats $0.10 Estimate, Sales $438.900M Miss $438.910M Estimate

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
NeuroOne Medical Tech (NASDAQ:<a href="https://investorplace.com/stock-quotes/nmtc-stock-quote/">NMTC</a>) just reported results for the second quarter of 2024.<ul><li>NeuroOne Medical Tech reported earnings per share of -11 cents. This was below the analyst estimate for EPS of -10 cents.</li><li>The company reported revenue of $1.38 million.</li><li>This was 19% worse than the analyst estimate for revenue of $1.70 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/nmtc-stock-earnings-neuroone-medical-tech-for-q2-of-2024/">NMTC Stock Earnings: NeuroOne Medical Tech Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NMTC Stock Earnings: NeuroOne Medical Tech Misses EPS, Misses Revenue for Q2 2024

NeuroOne Medical Technologies Corporation (NMTC) Q2 2024 Earnings Call Transcript

NeuroOne Medical files $150M mixed securities shelf

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
If the prospect of controlling computers and robots with brainpower alone excites you, neurotech stocks are right up your alley. Unfortunately, today&rsquo;s top neurotech company &mdash; Elon Musk&rsquo;s Neuralink &mdash; remains off-limits to retail investors. But that doesn&rsquo;t mean there isn&rsquo;t plenty of opportunity elsewhere in public markets.



Neurotech stocks are in a somewhat tricky position for all but the most speculative and risk-on investors; the sector is ascendant, true, but combines the volatility of <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> with the inherent risk of small-cap tech startups. At the same time, these companies are often pre-revenue and R&amp;D-intensive, which creates a unique series of cash flow problems that could bankrupt even the most promising neurotech stock.



To that end, these neurotech stocks have some of the best potential among an admittedly small field &mdash; but they&rsquo;re riskier than more mundane options, even if the potential rewards outweigh the negatives.



<h2>NeuroOne Medical Technologies (NMTC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biomedical-technology1600-300x169.png" alt="Modern Medical Research Laboratory with Computer, Microscope, Glassware with Biochemicals on the Desk. Scientific Lab Biotechnology Development Center Full of High-Tech Equipment. Biomedical technology stocks, RSLS Stock"><div>Source: Gorodenkoff / Shutterstock.com</div></div>NeuroOne Medical Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/nmtc-stock-quote/">NMTC</a>) is one of today&rsquo;s best options among neurotech stocks, as the firm&rsquo;s <a href="https://nmtc1.com/technology">proprietary electrodes</a> are thin and flexible enough to map easily onto the human brain (relatively and comparatively speaking, that is). NeuroOne&rsquo;s current ambitions don&rsquo;t yet scale to Musk&rsquo;s, but that&rsquo;s a good thing: a small-cap neurotech stock, NeuroOne is starting small and focusing on key healthcare monitoring tasks to pivot upward as cash begins coming in eventually.NeuroOne&rsquo;s primary current core offerings is OneRF, which helps monitor and detect seizures for epileptic patients.



But they aren&rsquo;t stopping there.



Last year, NeuroOne unveiled plans to <a href="https://www.drugdeliverybusiness.com/neuroone-pursuing-drug-delivery-neural-probes/">develop drug delivery mechanisms</a> leveraging neural probes, which could prove a boon to many medications that have trouble traversing the notoriously impenetrable blood-brain barrier. If the plans come to fruition, NeuroOne could be a major contributor to patient outcomes across a range of healthcare applications.



<h2>Neuronetics (STIM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div>Neuronetics (NASDAQ:<a href="https://investorplace.com/stock-quotes/stim-stock-quote/">STIM</a>) treats psychiatric and mental health disorders leveraging neuromodulation tech primarily consisting of transcranial magnetic stimulation, a minimally-invasive outpatient procedure involving external <a href="https://www.mayoclinic.org/tests-procedures/transcranial-magnetic-stimulation/about/pac-20384625">magnetic field application</a>. Its treatment is proven if not widespread, and has <a href="https://neurostar.com/neuronetics/clinical-evidence/">helped more than</a> 175,000 patients nationally over the course of more than 6.4 million treatment applications.



Compared to alternatives, Neuronetics&rsquo; tools maintained durability for twelve months or longer, meaning treatment effects took longer to wear off with fewer visits required. The application also has a shockingly high response rate at 83% and low remission rate of 62%. This may be one major contributor to why most haven&rsquo;t heard of the neurotech stock &mdash; treatments this effective pose a risk to pharma&rsquo;s bottom line, and could ultimately make many existing therapeutics obsolete if the firm&rsquo;s depression treatments continue performing.



Still, Neuronetics is making rapid inroads toward wider adoption, which includes a recent Medicaid win that opens the door to transcranial magnetic stimulation access for <a href="https://ir.neuronetics.com/news-releases/news-release-details/california-medicaid-adds-tms-access-148-million-adolescents-and">more than 14 million</a> adolescents and adults in California.



<h2>Medtronic (MDT)</h2>



<div><img width="300" height="165" src="https://investorplace.com/wp-content/uploads/2018/08/mdtmsn-300x165.jpg" alt="A photo of a Medtronic PLC (MDT) sign outside a building."><div>Source: Shutterstock</div></div>Medtronic&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/mdt-stock-quote/">MDT</a>) isn&rsquo;t a pure-play neurotech stock, but it still stands out as having latent potential to secure a sizable chunk of the market as tech advances. The MedTech company is already known for forward-thinking initiatives that include a partnership with Nvidia (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvda-stock-quote/">NVDA</a>) to develop AI-enabled diagnostics. Assuming that Medtronic will position itself as a neurotech stock as the sector matures is only reasonable.



Medtronic already offers a range of <a href="https://www.medtronic.com/us-en/healthcare-professionals/products/neurological.html">peripheral products</a>, including cranial robotics, deep brain stimulation and spinal cord neurostimulation systems. Morever, Medtronic operates in more than <a href="https://www.medtronic.com/us-en/our-company/key-facts.html">150 countries</a>, all but assuring rapid market penetration as neurotech tools comes to the fore.



Interested investors can even see a possible sneak peek of Medtronic&rsquo;s planned forays into neurotech, as a staff member will be speaking at a July 29th <a href="https://thedaily.case.edu/summer-neurotech-talk/">NeuroTech Talk conference</a>. While Medtronic hasn&rsquo;t sanctioned the talk, nor is it intended to reveal any company-specific plans, it offers an enlightening look into an emerging industry from undeniable experts.



On the date of publication, Jeremy Flint held no positions in the securities mentioned. The opinions expressed in this article are those of the writer, subject to the <a href="http://InvestorPlace.com">InvestorPlace.com</a> <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Jeremy Flint, an MBA graduate and skilled finance writer, excels in content strategy for wealth managers and investment funds. Passionate about simplifying complex market concepts, he focuses on fixed-income investing, alternative investments, economic analysis, and the oil, gas, and utilities sectors. Jeremy&rsquo;s work can also be found at <a href="https://jeremyflint.work/">www.jeremyflint.work</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/07/3-neurotech-stocks-bridging-mind-and-machine/">3 Neurotech Stocks Bridging Mind and Machine</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Neurotech Stocks Bridging Mind and Machine

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Problems with <a href="https://www.labiotech.eu/best-biotech/neuroscience-biotech-companies/">the central nervous system</a> are the second leading cause of death globally, the World Health Organization determined in 2022. One reason for this situation is that it&rsquo;s extremely difficult to develop effective treatments for these disorders because of the complexity of the CNS, European biotech news website Labiotech reported last year. Further, the blood-brain barrier that stops damaging substances from entering our brains also prevents many drugs from impacting the organ. 



In general, finding safe, effective drugs that insurers will pay for and that will be better than standard-of-care treatments is an extremely long, arduous process that&rsquo;s unlikely to succeed. Given the enhanced difficulties involved with developing neurological treatments, companies in that space have an even harder road to traverse. 



But the good news for investors is that, if companies do develop successful neurological drugs, they probably won&rsquo;t face much tough competition. With that in mind, here are the three best neuroscience <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> to buy now.



<h2>Vertex (VRTX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/06/vrtx-stock-1-300x169.jpg" alt="Vertex Pharmaceuticals (VRTX) logo visible on display screen"><div>Source: Pavel Kapysh / Shutterstock.com</div></div>Pain is <a href="https://www.arthritis.org/health-wellness/healthy-living/managing-pain/understanding-pain/pain-brain-connection">a neurological phenomenon</a>. Consequently, Vertex&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/vrtx-stock-quote/">VRTX</a>) moderate-to-severe acute pain treatment, called suzetrigine, can be viewed as a neurological drug. Importantly, suzetrigine is a <a href="https://www.clinicaltrialsarena.com/news/vertex-aims-for-approval-after-phase-iii-win-with-non-opioid-pain-reliever/">non-opioid pain medication</a>, making it much less addictive than the powerful opioid pain treatments widely used today.



Vertex CEO Reshma Kewalramani explained that his company&rsquo;s drug can &ldquo;potentially fill the gap&rdquo; between very safe but fairly weak painkillers and strong, opioid painkillers that can easily become addictive.



In a Phase-3 trial, suzetrigine successfully reduced patients&rsquo; surgical and non-surgical pain meaningfully more than a placebo. However, it failed to lessen patients&rsquo; pain significantly more than a combination of the opioid drug hydrocodone and acetaminophen.&nbsp;



Nonetheless, GlobalData has estimated that the drug will generate a significant $1.4 billion of revenue for Vertex in 2030. Other analysts believe <a href="https://www.biopharmadive.com/news/vertex-pain-drug-fda-approval-filing-opioid/713568/">that the treatment could</a> generate multi-billion dollar peak annual revenue.



Vertex <a href="https://finance.yahoo.com/news/vertex-announces-advancements-suzetrigine-vx-120000605.html">hoped to finish submitting</a> the drug to the FDA for its approval as a treatment for &ldquo;moderate to severe pain&rdquo; by the end of last quarter.



Given the strong potential of Vertex&rsquo;s non-addictive painkiller, I view it as one of the best biotech stocks to buy at this point. 



<h2>Eisai (ESAIY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/07/alzheimers1600-300x169.png" alt="Alzheimer's disease concept, Elderly woman holding brain symbol of missing jigsaw puzzle, World Alzheimer's, World mental health, Memory loss, Dementia, Parkinson disease."><div>Source: PopTika / Shutterstock.com</div></div>As I&rsquo;ve noted in previous columns, Eisai&rsquo;s (OTCMKTS:<a href="https://investorplace.com/stock-quotes/esaiy-stock-quote/">ESAIY</a>) Alzheimer&rsquo;s drug, Leqembi, <a href="https://www.biospace.com/eisai-biogen-build-case-for-subcutaneous-leqembi-for-alzheimer-s-at-ctad">actually improved </a>the cognition capabilities of 60% of patients thought to be in the early stages of the disease.



Meanwhile, in May Eisai began <a href="https://www.eisai.com/news/2024/news202430.html">a rolling submission</a> of a Biologics License Application (BLA) for a subcutaneous version of the drug. If approved, this version, unlike the intravenous version that&rsquo;s already being utilized, can be administered to patients in doctors&rsquo; offices and in homes. Additionally, the drug can be delivered more quickly via the subcutaneous mechanism than through IV, Eisai reported. Given these points, I believe that the demand for Leqembi will greatly increase after the subcutaenous version of it is released.



By fiscal 2026, Eisai <a href="https://www.fiercepharma.com/pharma/eisai-dials-sales-ambitions-alzheimers-med-leqembi-amid-launch-growing-pains">predicts that the drug&rsquo;s</a> sales can reach almost $2 billion in its fiscal year that ends in March 2027 and $8.8 billion in its fiscal year that ends in March 2033. 



Given Leqembi&rsquo;s strong efficacy and the lack of strong competition in the Alzheimer&rsquo;s treatment space, I believe that the drug&rsquo;s revenue can significantly exceed those targets. Consequently, I believe that the company, which currently has a market capitalization of almost $12 billion, is significantly undervalued and is one of the best biotech stocks to buy now.



<h2>NeuroOne Medical (NMTC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-300x169.png" alt="Medical technology network team meeting concept. Doctor hand working smart phone modern digital tablet laptop computer graphics chart interface, sun flare effect photo, PTE"><div>Source: everything possible / Shutterstock.com</div></div>NeuroOne (NASDAQ:<a href="https://investorplace.com/stock-quotes/nmtc-stock-quote/">NMTC</a>) develops products using thin film electrode technology.&nbsp;Its offerings are being used to facilitate electroencephalograms or EEGs <a href="https://www.mayoclinic.org/tests-procedures/eeg/about/pac-20393875#:~:text=An%20electroencephalogram%20(EEG)%20is%20a,lines%20on%20an%20EEG%20recording.">which determine the extent</a> of electrical activity in the brain. NeuroOne&rsquo;s products are also being used in conjunction with &nbsp;spinal cord stimulation and brain stimulation.



Provoiding significant validation for NeurOne and its products, the firm <a href="https://seekingalpha.com/article/4651466-neuroone-a-hidden-contender-against-clearpoint-in-the-brain-drug-delivery-arena">partners with two </a>very prestigious hospitals, Mayo Clinic and Cleveland Clinic. Additionally, the firm collaborates with a huge medical device company, Zimmer Biomet (NYSE:<a href="https://investorplace.com/stock-quotes/zbh-stock-quote/">ZBH</a>).



Also impressively, NeuroOne is only nine healthcare firms whose stock is owned by the Mayo Clinic.



Moreover, NeuroOne is <a href="https://seekingalpha.com/news/4106153-neuroone-medical-technologies-gaap-eps-of--011">growing at an impressive rate</a> as its product revenue jumped to $1.38 million last quarter compared to $466,000 during the same period a year earlier.



On the date of publication, Larry Ramer held a long position in ESAIY. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.&nbsp;&nbsp;



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;
<div>Larry Ramer has conducted research and written articles on U.S. stocks for 15 years. He has been employed by The Fly and Israel&rsquo;s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been SMCI, INTC, and MGM. You can reach him on Stocktwits at @larryramer.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/07/the-3-best-neuroscience-biotech-stocks-to-buy-now/">The 3 Best Neuroscience Biotech Stocks to Buy Now</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

The 3 Best Neuroscience Biotech Stocks to Buy Now

NeuroOne Medical Technologies GAAP EPS of -$0.10, revenue of $825.7M

NeuroOne Medical Technologies Corporation (NMTC) Q3 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
NeuroOne Medical Tech (NASDAQ:<a href="https://investorplace.com/stock-quotes/nmtc-stock-quote/">NMTC</a>) just reported results for the third quarter of 2024.<ul><li>NeuroOne Medical Tech reported earnings per share of -10 cents. This met the analyst estimate for EPS of -10 cents.</li><li>The company reported revenue of $825,776.</li><li>This was 58.71% worse than the analyst estimate for revenue of $2.00 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/nmtc-stock-earnings-neuroone-medical-tech-for-q3-of-2024/">NMTC Stock Earnings: NeuroOne Medical Tech Meets EPS, Misses Revenue for Q3 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NMTC Stock Earnings: NeuroOne Medical Tech Meets EPS, Misses Revenue for Q3 2024

NeuroOne Medical files to sell 5.5M shares of common stock for holders

NeuroOne Medical Technologies ( ($NMTC) ) has shared an announcement. NeuroOne Medical Technologies Corporation has updated the severance benefits ...

NeuroOne Enhances Executive Severance Packages Amid Takeover Possibility

ESAIY

NMTC

NVDA

STIM

VRTX

Screenshot 2024-05-03 at 5.56.54 PM

Biotech

Interview

NeuroOne – The Medical Device Company That Has Created A Product That Could Monitor And Treat At The Same Time

Screenshot 2024-03-27 at 5.33.58 PM

NeuroOnes&#39;s Innovative Electrode Brain Monitoring Seeks To Provide Insights Into Neurological Disorders

Screenshot 2024-03-07 at 8.32.36 PM

Health Care

Movers & Shakers

ATITK

NeuroOne Medical Technologies&#39; (NASDAQ: NMTC) Innovative Brain Monitoring Tech Developing And Commercializing Electrodes To Provide Insights To Help Physicians Treat Neurological Disorders Like Epilepsy

Comments

NeuroOne Medical Tech

Vendite allo scoperto

NeuroOne Medical Tech (NASDAQ:NMTC) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO